Long Ideas - Synergy Pharmaceuticals (NASDAQ:SGYP) recently submitted an IND (Investigational New Drug application) for its IBD (inflammatory bowel disease) treatment, SP-333, and is on track to meet … Continue Reading
Read nowLong Ideas - Forest Laboratories (NYSE:FRX) and partner Ironwood Pharmaceuticals (NASDAQ:IRWD) announced FDA approval of Linzess (generically known as linaclotide) for the treatment of irritable bowel syndrome with … Continue Reading
Read nowLong Ideas - Amarin Pharmaceuticals (NASDAQ:AMRN) could trade higher as investors digest this morning’s news that Roche’s (OTC:RHHBY) former Head of Global Pharmaceuticals has joined AstraZeneca (NYSE:AZN) as … Continue Reading
Read nowLong Ideas - Synergy Pharmaceuticals (NASDAQ:SGYP) announced today that its Phase IIb/III trial testing lead drug plecanatide for chronic constipation is fully enrolled. The trial met its 880 … Continue Reading
Read now- Synergy Pharmaceuticals (NASDAQ: SGYP) announced Friday that it plans to merge with Callisto Pharmaceuticals (NASDAQ: CLSP), which happens to be Synergy’s largest shareholder. SGYP is … Continue Reading
Read now- Sucampo Pharmaceuticals (SCMP) said on Friday that the International Court of Arbitration, International Chamber of Commerce (ICC) did not agree with its claims against partner, … Continue Reading
Read now